The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that ...

J&J will hand over the rights to bota-vec for $25 million upfront, clearing MeiraGTx to seek regulatory approvals in the U.S.

Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data ...

In this episode of Denatured, you'll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed ...

Erica Schwartz, a former deputy surgeon general and member of the U.S. military, will take over from what has amounted to a ...

Despite exceptional regional hubs and research strength, investors say Europe still needs more integrated incubators, smarter ...

Greater transparency in FDA decision-making was possibly the most common theme for stakeholders interviewed by the Institute ...

With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory ...

In recent months, Anthropic has been building more and more ties with the biopharma industry, including partnerships with Big ...

After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to ...

Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data ...

The trend of fewer companies letting employees go, which began in the fourth quarter of last year, has continued. However, ...